Tenaya Therapeutics Inc Stock
Tenaya Therapeutics Inc Stock price
Key metrics
| Market capitalization | $79.22m |
| Enterprise Value | $14.29m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 0.70 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-122.74m |
| Free Cash Flow (TTM) Free Cash Flow | $-95.25m |
| Cash position | $79.47m |
Is Tenaya Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
Tenaya Therapeutics Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Tenaya Therapeutics Inc forecast:
Analyst Opinions
9 Analysts have issued a Tenaya Therapeutics Inc forecast:
Financial data from Tenaya Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -9.37 -9.37 |
20%
20%
|
|
| EBITDA | -113 -113 |
8%
8%
|
EBIT (Operating Income) EBIT | -123 -123 |
9%
9%
|
| Net Profit | -117 -117 |
8%
8%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Tenaya Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tenaya Therapeutics Inc Stock News
Company Profile
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Faraz Ali |
| Employees | 140 |
| Founded | 2016 |
| Website | www.tenayatherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
